69
/ 100
Mostly True
London
The website discusses an experimental Alzheimer's drug, diranersen, which shows promise in reducing tau levels and slowing cognitive decline, though its effectiveness is still uncertain.
Infact verdict: Mostly True (69/100).
The claims about diranersen, an experimental Alzheimer's drug, are largely supported by evidence from multiple sources. The drug shows promise in reducing tau levels in cerebrospinal fluid and slightly slowing cognitive decline, although its overall effectiveness is still under evaluation. The mechanism of action, involving the MAPT gene, is well-documented. However, the claim that diranersen can 'sweep' tau tangles from the brain is more optimistic than the evidence supports, as the drug is still in clinical trials and not yet approved. Overall, the claims are mostly accurate, with some requiring cautious interpretation due to the ongoing nature of the research.
How is this score determined? →Individual claims
69
Mostly True
Health
An experimental drug called diranersen can sweep tangles of tau from the brain.
The evidence indicates that diranersen targets tau protein to reduce its levels in the brain, which is a promising approach for Alzheimer's treatment. However, the drug is still in clinical trials and not yet approved, meaning its effectiveness is still under evaluation. Multiple sources, including Science News and AP News, corroborate the claim that diranersen targets tau protein, but the claim that it can 'sweep' tau tangles is more optimistic than the evidence supports.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
75
Web Consensus Weight
40
Source Quality Score
70
Source Quality Weight
20
Llm Reasoning Score
75
Llm Reasoning Weight
40
Llm Reasoning Score Raw
None
Weighted Total
69
Evidence Summary
Multiple sources confirm diranersen targets tau protein, but its effectiveness is still under evaluation.
90
True
Health
Diranersen reduced tau levels in patients’ cerebrospinal fluid by between 50 and 65 percent.
The claim is supported by multiple sources, including Science News and Markets Insider, which report that diranersen reduced tau levels in cerebrospinal fluid by 50-65%. This is consistent across different reports, indicating a strong consensus on this specific outcome of the clinical trial.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
85
Web Consensus Weight
40
Source Quality Score
80
Source Quality Weight
20
Llm Reasoning Score
85
Llm Reasoning Weight
40
Llm Reasoning Score Raw
None
Weighted Total
90
Evidence Summary
Multiple sources confirm tau reduction by 50-65% in cerebrospinal fluid.
67
Mostly True
Health
Diranersen seemed to slightly slow people’s cognitive decline compared with those given a placebo.
The evidence from sources like Science News and Neurology Live indicates that diranersen showed a slight slowing of cognitive decline in Alzheimer's patients compared to placebo. This is supported by multiple clinical endpoints in the Phase 2 trial, suggesting a moderate level of effectiveness.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
70
Web Consensus Weight
40
Source Quality Score
75
Source Quality Weight
20
Llm Reasoning Score
70
Llm Reasoning Weight
40
Llm Reasoning Score Raw
None
Weighted Total
67
Evidence Summary
Multiple sources report slight slowing of cognitive decline in trials.
28
Mostly False
Health
The Phase II trial of diranersen recruited 416 participants with mild cognitive impairment or early-stage Alzheimer’s disease.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
None
Web Consensus Weight
40
Source Quality Score
None
Source Quality Weight
20
Llm Reasoning Score
50
Llm Reasoning Weight
40
Llm Reasoning Score Raw
None
Weighted Total
28
Evidence Summary
None
93
True
Health
Diranersen is an antisense oligonucleotide that binds to the MAPT gene.
The claim is supported by evidence from MedChemExpress and Drugs.com, which describe diranersen as an antisense oligonucleotide targeting the MAPT gene to reduce tau protein production. This is a well-documented mechanism of action for the drug.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
90
Web Consensus Weight
40
Source Quality Score
85
Source Quality Weight
20
Llm Reasoning Score
90
Llm Reasoning Weight
40
Llm Reasoning Score Raw
None
Weighted Total
93
Evidence Summary
Multiple sources confirm diranersen targets the MAPT gene.
